MASSANO, DAVIDE
 Distribuzione geografica
Continente #
NA - Nord America 196
AS - Asia 91
EU - Europa 76
AF - Africa 13
OC - Oceania 1
Totale 377
Nazione #
US - Stati Uniti d'America 180
IT - Italia 44
CN - Cina 23
TR - Turchia 18
IN - India 17
CA - Canada 16
DE - Germania 11
EG - Egitto 11
GB - Regno Unito 5
IQ - Iraq 5
SG - Singapore 5
FR - Francia 4
IE - Irlanda 4
IR - Iran 4
JO - Giordania 3
JP - Giappone 3
KR - Corea 3
TH - Thailandia 3
ID - Indonesia 2
TW - Taiwan 2
VN - Vietnam 2
AU - Australia 1
DK - Danimarca 1
GR - Grecia 1
HU - Ungheria 1
LT - Lituania 1
MA - Marocco 1
NL - Olanda 1
PK - Pakistan 1
RO - Romania 1
RU - Federazione Russa 1
SE - Svezia 1
ZA - Sudafrica 1
Totale 377
Città #
Fairfield 28
Houston 28
Torino 25
Ashburn 14
Istanbul 14
Woodbridge 14
Ottawa 13
Beijing 12
Seattle 12
Ann Arbor 10
Santa Cruz 8
Buffalo 7
Cambridge 7
Wilmington 7
University Park 4
Mumbai 3
Bangkok 2
Bengaluru 2
Bricherasio 2
Cairo 2
Clearwater 2
Dong Ket 2
Dublin 2
Fremont 2
Gurgaon 2
Hamburg 2
Hangzhou 2
Hartford 2
Henderson 2
Los Angeles 2
Riva 2
San Diego 2
Savona 2
Shanghai 2
Taipei 2
Aachen 1
Acton 1
Ahmedabad 1
Ankara 1
Ardabil 1
Bad Vilbel 1
Bangalore 1
Bari 1
Bekasi 1
Boiling Springs 1
Boulder 1
Burlington 1
Chicago 1
Copenhagen 1
Fairport 1
Gothenburg 1
Isfahan 1
Jakarta 1
Jiaxing 1
Jinan 1
Kiel 1
Kundan 1
Lake Forest 1
Milledgeville 1
Mountain View 1
Muizenberg 1
New York 1
Niagara Falls 1
Nürnberg 1
Phoenix 1
Piemonte 1
Pietra Ligure 1
Ramsis 1
Rivalta Di Torino 1
San Jose 1
Scranton 1
Si Sa Ket 1
Singapore 1
Tianjin 1
Tokyo 1
Toronto 1
Turin 1
Wageningen 1
Warangal 1
Wuhan 1
Yellow Springs 1
Totale 290
Nome #
A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients., file e27ce429-e7ed-2581-e053-d805fe0acbaa 281
Influence of single-nucleotide polymorphisms on deferasirox C-trough levels and effectiveness, file e27ce427-f197-2581-e053-d805fe0acbaa 65
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes, file e27ce42b-fd4b-2581-e053-d805fe0acbaa 10
Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children, file a8c804c5-7365-42d1-ad56-c4f1fca0ab19 8
Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia, file e27ce42a-ed50-2581-e053-d805fe0acbaa 3
Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children, file e27ce42c-1042-2581-e053-d805fe0acbaa 3
Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients, file e27ce42d-5e98-2581-e053-d805fe0acbaa 3
The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients, file e27ce42d-94fe-2581-e053-d805fe0acbaa 3
A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients., file e27ce429-e7f4-2581-e053-d805fe0acbaa 2
Deferasirox AUC efficacy cutoff and role of pharmacogenetics, file e27ce42a-907d-2581-e053-d805fe0acbaa 2
Role of pharmacogenetics on deferasirox AUC and efficacy, file e27ce42a-c6a0-2581-e053-d805fe0acbaa 2
Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients, file e27ce42b-ab62-2581-e053-d805fe0acbaa 2
Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients, file e27ce42b-c5f3-2581-e053-d805fe0acbaa 2
Clinical relevance of deferasirox trough levels in β-thalassemia patients, file e27ce42c-5f9e-2581-e053-d805fe0acbaa 2
Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment, file e27ce42a-e7b9-2581-e053-d805fe0acbaa 1
Totale 389
Categoria #
all - tutte 516
article - articoli 0
book - libri 0
conference - conferenze 157
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 673


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201922 0 0 0 0 0 0 0 0 0 6 7 9
2019/202070 5 3 3 8 7 3 5 13 7 5 3 8
2020/202173 3 7 5 3 2 19 2 7 2 4 14 5
2021/2022107 6 12 2 25 10 3 7 16 3 7 7 9
2022/202345 3 4 18 3 4 3 2 4 0 1 3 0
2023/20248 3 0 0 0 1 0 2 1 0 1 0 0
Totale 389